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Objectives: The aim of this study was to develop and validate a population pharmacokinetic model to:
(i) describe ritonavir-boosted atazanavir concentrations (300/100 mg once daily) and identify important
covariates; and (ii) evaluate the predictive performance of the model for lower, unlicensed atazanavir
doses (150 and 200 mg once daily) boosted with ritonavir (100 mg once daily).
Methods: Non-linear mixed effects modelling was applied to determine atazanavir pharmacokinetic par-
ameters, inter-individual variability (IIV) and residual error. Covariates potentially related to atazanavir
pharmacokinetics were explored. The ﬁnal model was assessed by means of a visual predictive check
for 300/100, 200/100 and 150/100 mg once daily.
Results: Forty-six individuals were included (30 HIV-infected). A one-compartment model with ﬁrst-
order absorption and lag-time best described the data. Final estimates of apparent oral clearance (CL/F),
volume of distribution (V/F) and absorption rate constant [relative standard error (%) and IIV (%)] were
7.7 L/h (5, 29), 103 L (13, 48) and 3.4 h
21 (34, 154); a lag-time of 0.96 h (1) was determined. Ritonavir area
under the curve (AUC0–24) was the only signiﬁcant covariate. Overall, 94%–97% of observed concen-
trations were within the 95% prediction intervals for all three regimens.
Conclusions: A population pharmacokinetic model for ritonavir-boosted atazanavir has been developed
and validated. Ritonavir AUC0–24was signiﬁcantly associated with atazanavir CL/F. The model was used
to investigate other, particularly lower, ritonavir-boosted atazanavir dosing strategies.
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Introduction
Atazanavir (REYATAZ
w, Bristol–Myers Squibb, Princeton, NJ,
USA) is a protease inhibitor used as part of combination therapy
in the treatment of HIV disease. It is approved in Europe and
the USA at a dose of 300 mg boosted with ritonavir (NORVIR
w,
Abbott Laboratories, Chicago, IL, USA) 100 mg once daily
(atazanavir/ritonavir 300/100 mg once daily) to be taken with
food,
1,2 but is also approved in the USA unboosted at 400 mg
once daily for treatment-naive patients.
1 Atazanavir beneﬁts
from once-daily dosing, low pill burden and also a favourable
safety proﬁle with less lipid abnormalities than other protease
inhibitors.
3 Atazanavir is metabolized by CYP3A4/3A5
1,2 and
is an inhibitor of CYP3A4, p-glycoprotein
4 and UDP-
glucuronosyltransferase 1A1 (UGT1A1)
5; therefore, the potential
for drug–drug interactions is high. Important interactions with
proton-pump inhibitors
6,7 and unexpectedly with tenofovir
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8,9
have been documented and patients may beneﬁt from therapeutic
drug monitoring (TDM) in this context. A therapeutic target
concentration of 0.15 mg/L at trough has been deﬁned as an
optimal concentration for successful viral suppression
10 and an
upper limit .0.85 mg/L has been associated with a risk of
increased unconjugated bilirubin and incidences of hyperbiliru-
binaemia
11 due to UGT1A1 inhibition.
High inter-individual variability in atazanavir drug concen-
trations has been observed and can be a result of several factors
including drug–drug interactions, lack of regard for food
recommendations (or for whatever reason, being unable to gain
access to food at the time of drug intake) and suboptimal treat-
ment adherence. Identifying sources of variability in pharmaco-
kinetics is important in the clinical management of HIV
infection and may aid optimal dosage selection. The aim of the
present analysis was to develop and validate a population phar-
macokinetic model to: (i) describe ritonavir-boosted atazanavir
concentrations (300/100 mg once daily) and identify important
covariates that may impact pharmacokinetic variability; and
(ii) simulate concentration–time proﬁles of lower, unlicensed
atazanavir doses (150 and 200 mg once daily) boosted with
ritonavir (100 mg once daily).
Methods
Patients
Data were included from three clinical studies conducted in healthy
adults (one study)
12 and HIV-infected patients (two studies)
13,14 evalu-
ating atazanavir/ritonavir pharmacokinetics dosed at 300/100 mg once
daily. All individuals were recruited and assessed at one UK study
centre (St Stephen’s Centre, Chelsea and Westminster Foundation
Trust, London, UK); all three studies were approved by the local
Research Ethics Committee, and patients and volunteers provided
written informed consent. Detailed accounts of study design, inclusion/
exclusion criteria and pharmacokinetic ﬁndings of each study have
been reported previously.
12–14 In summary, adult males and non-
pregnant females (.18 years) were permitted to enrol in the studies.
With the exception of HIV infection, individuals with active clinically
signiﬁcant conditions (such as hepatitis infections or tuberculosis)
were not eligible to participate. Intake of medications known to inﬂu-
ence protease inhibitor metabolism (such as non-nucleoside reverse
transcriptase inhibitors) was not permitted, and boosted atazanavir
was investigated as the sole protease inhibitor with the exception of
one study in which patients also received hard-gel saquinavir
(INVIRASE
w, Roche Pharmaceuticals, Nutley, NJ, USA; 1600 mg
once daily) in combination with atazanavir/ritonavir (300/100 mg
once daily).
13 Investigations suggest that co-administration of saquina-
vir does not affect atazanavir pharmacokinetics.
15,16 Patients were
allowed to receive tenofovir as part of their therapy backbone even
though some studies have shown a decrease in atazanavir concen-
trations in the presence of tenofovir.
8,9
Blood sampling and drug analysis
All individuals were stable on atazanavir/ritonavir at least 2 weeks
prior to the start of each study and HIV patients received atazanavir/
ritonavir in combination with two nucleoside reverse transcriptase
inhibitors (NRTIs) or one NRTI plus one nucleotide reverse tran-
scriptase inhibitor. Drug intake was directly observed and timed on
the day of pharmacokinetic sampling and administered under fed
conditions with a standardized meal (16–20 g fat). Venous blood
samples (7 mL) were drawn and collected into heparinized tubes
pre-dose (0 h) and 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h post-dose;
healthy volunteers had additional samples taken at 16 and 20 h
post-dose. Plasma was isolated (1000 g; 10 min; 48C) within 2 h of
collection and stored (2708C) until analysed.
Plasma atazanavir and ritonavir concentrations were determined
by fully validated high-performance liquid chromatography-tandem
mass spectrometry methods as illustrated previously.
17,18 All con-
centrations were assessed at one laboratory with the exception of
one study;
13 however, both laboratories participate in the same
external quality assurance programme (International Interlaboratory
Quality Control Program for Therapeutic Drug Monitoring in HIV
Infection, Nijmegen, The Netherlands) with acceptable perform-
ances. Details of each assay’s performance have been reported
previously.
17,18
Data analysis
Non-linear mixed effects modelling was applied using NONMEM
w
(version VI 2.0, level 1.1, double precision; ICON Development
Solutions, Ellicott City, MD, USA),
19 using ﬁrst-order conditional
estimation with interaction. Model ﬁt was assessed by statistical and
graphical methods. The minimal objective function value (OFV;
equal to 22 log likelihood) was used as a goodness-of-ﬁt diagnostic
with a decrease of 3.84 points corresponding to a statistically
signiﬁcant difference between hierarchical models (P¼0.05, x
2 dis-
tribution, one degree of freedom). Graphical diagnostics were per-
formed with Microsoft
w Ofﬁce Excel 2007 for Windows (Microsoft
Corporation, Redmond, WA, USA). Standard errors of the parameter
estimates were determined with the COVARIANCE option of
NONMEM
w and individual Bayesian parameter and concentration
estimates by the POSTHOC option.
Pharmacokinetic and covariate model building
To determine the best structural model to ﬁt the data, one- and two-
compartment models with ﬁrst- or zero-order absorption without
and with lag-time were considered. Proportional, additional and a
combined proportional–additional error model were evaluated to
describe residual variability. Although the two laboratories that per-
formed the drug analysis were part of the same quality assurance
scheme, error models were explored for the two laboratories to
determine whether separate assays contributed individually to the
residual variability.
Once a baseline model was established, the following covariates
were explored: ritonavir area under the curve over the dosing inter-
val (AUC0–24), HIV status, sex, ethnicity, weight, concomitant pro-
tease inhibitor use (saquinavir 1600 mg once daily) and tenofovir
use (300 mg once daily). For continuous variables (for example,
weight), plots of covariates versus individual predicted pharmacoki-
netic parameters were performed to determine possible relationships.
Each covariate was introduced separately and only retained if
inclusion in the model produced a statistically signiﬁcant decrease
in OFV of 3.84 (P 0.05), was biologically plausible and reduced
variability (by at least 10%). A backwards elimination step was
carried out once all relevant covariates were incorporated and
covariates retained if their removal from the model produced a
signiﬁcant increase in OFV (.6.63 points; P 0.01, x
2 distribution,
one degree of freedom). Ritonavir AUC0–24 was determined
from the concentration–time data using non-compartmental
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w 5.2, Pharsight Corporation, Mountain View,
CA, USA).
Model validation
To perform a visual predictive check, 1000 datasets were simulated
using the parameter estimates deﬁned by the ﬁnal model with
the SIMULATION SUBPROBLEMS option of NONMEM
w.
Datasets were simulated for atazanavir/ritonavir 300/100, 200/100
and 150/100 mg once daily. From the simulated data, 95% predic-
tion intervals (P2.5–P97.5) for each regimen were constructed.
Observed data from the original dataset were superimposed for
atazanavir/ritonavir 300/100 mg once daily. Concentration–time
data from patients participating in another external clinical study
receiving atazanavir/ritonavir/saquinavir 200/100/1600 and 150/100/
1600 mg once daily
20 were used to evaluate the prediction of lower
dose atazanavir. At least 95% of data points within the prediction
interval (2.5% above and below) was indicative of an adequate
model.
Bayesian estimation of trough concentrations and exposure
Using the observed data and ﬁnal model parameters, single samples
and combinations of two samples were used to estimate atazanavir
trough concentrations, i.e. concentrations 24 h post-dose and AUC0–24
[determined by dose/individual predicted apparent oral clearance
(CL/F)] of the HIV patients included in the analysis (300/100 mg once
daily). This was achieved by the addition of the missing data variable
column (MDV) to the data ﬁle to identify the concentration to be pre-
dicted by the model (i.e. concentration 24 h post-dose) and the exclu-
sion of the COVARIANCE step. Predicted trough concentrations and
AUC0–24 were compared with the observed values and the predictive
performance was evaluated by calculating mean relative prediction
error (%MPE) as a measure of bias and root mean squared relative
prediction error (%RMSE) as a measure of precision.
21 Observed
atazanavir AUC0–24 were determined by means of standard non-
compartmental methods (WinNonlin
w 5.2, Pharsight Corporation).
This process was also carried out with the lower dose ritonavir-
boosted atazanavir regimens (200/100 and 150/100 mg once daily).
Using the model and observed concentrations obtained at single
timepoints (2, 4, 6, 8, 10 and 12 h post-dose) from the external ata-
zanavir/ritonavir dataset,
20 predictions of trough concentrations
(24 h post-dose) and atazanavir AUC0–24 were performed and com-
pared with the observed values by the determination of %MPE and
%RMSE. Observed atazanavir AUC0–24 at doses of 200/100 and
150/100 mg once daily were calculated by means of standard non-
compartmental methods (WinNonlin
w 5.2, Pharsight Corporation).
Results
Patients
Sixteen healthy volunteers (6 female) and 30 HIV-infected
individuals (3 female) receiving orally administered atazanavir/
ritonavir were included in the model building process, the
demographics of whom are shown (Table 1). No difference in
age, weight or body mass index (BMI) was observed between
healthy volunteers and HIV patients (P 0.25 for all compari-
sons; unpaired t-test). Furthermore, ritonavir AUC0–24 was not
signiﬁcantly different between healthy and HIV-infected individ-
uals (7.36 versus 7.59 mg.h/L, P¼0.48; Mann–Whitney U-test).
In total, 538 concentrations were included (one pharmacokinetic
proﬁle per patient) ranging between 0.077 and 8.763 mg/L.
Pharmacokinetic model
A one-compartment model with ﬁrst-order absorption best
described the data. A one-compartment model with zero-order
absorption or a two-compartment model did not improve the ﬁt.
Compared with an additive error model, a proportional error
model improved the ﬁt (DOFV 2204.2). Inclusion of an addi-
tive component further improved the model with a pro-
portional–additive error model best describing residual
variability (DOFV 29.4) illustrated as follows:
Y ¼ F ð1 þ 11Þþ12
where Y is the ﬁnal prediction; F is the individual prediction;
and 11 and 12 are the proportional and additive model com-
ponents, respectively, with a mean of zero and variance s
2.
Inclusion of separate error models corresponding to the two
analytical laboratories did not improve the model (DOFV 21.2).
Inclusion of inter-individual variability (IIV) on volume of distri-
bution (V/F) signiﬁcantly improved model ﬁt (DOFV 284.6, com-
pared with IIV on CL/F alone), as did IIV on the absorption rate
constant (ka; DOFV 2122.5). Addition of an absorption lag-time
further improved ﬁt (DOFV 2176.8), but inclusion of IIV was not
signiﬁcant (DOFV 20.8). IIV was described by an exponential
model, an example of which is shown below for CL/F:
CL=Fi ¼ u1  expðhiÞ
where CL/Fi is the atazanavir CL/F of the ith individual; u1 is
the population parameter estimate; and hi is the IIV with a mean
of zero and variance v
2.
Parameter estimates for the basic model are summarized in
Table 2.
Covariate model
Once the basic structural model was deﬁned, covariates were
introduced one at a time to determine whether they inﬂuenced
atazanavir pharmacokinetics. For dichotomous variables, here
deﬁned as X (such as male/female sex and absence/presence of a
co-administered drug), the following equation was applied using
CL/F as an example:
TVCL ¼ u1  u X
2
where TVCL is the typical value of atazanavir CL/F of the
population; u1 is the value of CL/F for the individuals X¼0;
and u2 is the relative difference in CL/F for the individuals
X¼1.
Continuous variables were introduced into the model by
linear functions. Based on graphical plots of ritonavir AUC0–24
and pharmacokinetic parameters, exponential and power func-
tions were explored. Following univariate analysis, ritonavir
AUC0–24, concomitant use of saquinavir and weight were sig-
niﬁcantly associated with atazanavir CL/F and V/F, and Hispanic
ethnicity was signiﬁcantly associated with atazanavir CL/F
and ka (Table 3). However, once multivariate analysis and
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on atazanavir CL/F and V/F remained. Inclusion of ritonavir
AUC0–24 on atazanavir V/F failed to reduce IIV of this par-
ameter by .10% and therefore was removed from the ﬁnal
model (Table 2). The association of ritonavir AUC0–24 and ata-
zanavir CL/F was described by a power relationship, illustrated
below:
CL=Fi ¼ u1  ðRTVi=7:52Þ
u2
where CL/Fi is the atazanavir CL/F of the ith individual; u1
is the population parameter estimate; RTVi is the ritonavir
AUC0–24 of the ith individual; 7.52 is the median ritonavir
AUC0–24 of all individuals expressed as mg.h/L; and u2 is the
factor associated with ritonavir AUC0–24on atazanavir CL/F.
A power relationship between atazanavir CL/F and ritonavir
AUC0–24 was associated with a greater drop in both OFV and
IIV in CL/F compared with a linear (DOFV, DIIV: 244.6,
219% versus 227.4, 213%) and an exponential function
(244.6, 219% versus 235.5, 216%). Parameter estimates for
the ﬁnal model are summarized (Table 2) and goodness-of-ﬁt
diagnostic plots shown (Figure 1).
Internal model validation
A 95% prediction interval was generated from 1000 simulations
for atazanavir/ritonavir 300/100 mg once daily, one proﬁle per
patient (n¼46 patients; 46000 proﬁles in total) with covariate
values of those individuals used in the model building process
(Figure 2). Observed data from patients used in the model build-
ing process were superimposed onto the prediction interval. Of
538 concentrations, 2% were above P97.5 and 4% were below
P2.5 (Figure 2). This analysis suggests that the ﬁnal model pro-
vided an adequate ﬁt to the data with 94% of concentration data
falling within the prediction interval.
Table 1. Summary of patient demographics and baseline clinical characteristics
Parameter n (%) Median (range)
Study participants [M/F]
healthy volunteers 16 (35) [10/6]
HIV-infected 30 (65) [27/3]
Ethnicity
Caucasian 33 (72)
Black-African 7 (15)
Hispanic 6 (13)
Regimen
ATV/RTV 300/100 mg once daily 28 (61)
a
ATV/RTV/SQV 300/100/1600 mg once daily 18 (39)
TDF 300 mg once daily 6 (13)
Age (years)
healthy volunteers 42 (25–55)
HIV-infected 43 (22–62)
all 43 (22–62)
Weight (kg)
healthy volunteers 85 (53–115)
HIV-infected 76 (46–110)
all 76 (46–115)
BMI (kg/m
2)
healthy volunteers 25 (20–32)
HIV-infected 24 (15–38)
all 24 (15–38)
RTVAUC0–24(mg.h/L)
healthy volunteers 7.36 (4.31–13.42)
HIV-infected 7.59 (2.41–22.05)
all 7.52 (2.41–22.05)
Baseline CD4 cell count (cells/mm
3) 434 (10–1181)
Baseline HIV-RNA (copies/mL) 61 (,50–72)
n, number of patients; M, male; F, female; ATV, atazanavir; RTV, ritonavir; SQV, saquinavir; TDF, tenofovir; AUC0–24, area under the concentration–time
curve.
an¼16 healthy volunteers.
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were made using single or a combination of two measured con-
centrations from each HIV-infected individual (n¼30) and then
compared with measured trough concentrations and AUC0–24 by
means of %RMSE and %MPE (Table 4). A %RMSE ,15% and
%MPE not signiﬁcantly different from zero were indicative of
an acceptable predictive performance. An example of individual
predictions of atazanavir trough and AUC0–24 compared with
Table 3. Models explored to determine the inﬂuence of covariates on atazanavir pharmacokinetic parameters following univariate analysis
Covariate Model u1 u2 DOFV P value
Inﬂuence of RTV AUC0–24on CL/F CL¼u1*(RTV/7.52)
u2 7.66 20.84 244.6 ,0.001
Inﬂuence of RTV AUC0–24on V/F V¼u1*(RTV/7.52)
u2 104 20.50 210.1 ,0.01
Inﬂuence of HIV status on CL/F CL¼u1*u2
HIV 8.73 0.80 22.2 NS
Inﬂuence of HIV status on V/F V¼u1*u2
HIV 118 0.81 21.8 NS
Inﬂuence of HIV status on ka ka¼u1*u2
HIV 2.77 1.42 20.4 NS
Inﬂuence of SQV on CL/F CL¼u1*u2
SQV 8.86 0.67 28.3 ,0.01
Inﬂuence of SQV on V/F V¼u1*u2
SQV 123 0.64 29.4 ,0.01
Inﬂuence of TDF on CL/F CL¼u1*u2
TDF 7.75 0.83 20.8 NS
Inﬂuence of TDF on V/F V¼u1*u2
TDF 108 0.71 22.3 NS
Inﬂuence of TDF on ka ka¼u1*u2
TDF 3.43 1.10 20.0 NS
Inﬂuence of sex on CL/F CL¼u1*u2
SEX 7.95 0.77 22.0 NS
Inﬂuence of sex on V/F V¼u1*u2
SEX 98.7 1.26 21.5 NS
Inﬂuence of Black-African ethnicity on CL/F CL¼u1*u2
AFR 7.67 0.91 20.2 NS
Inﬂuence of Black-African ethnicity on V/F V¼u1*u2
AFR 100 1.23 21.0 NS
Inﬂuence of Black-African ethnicity on ka ka¼u1*u2
AFR 3.28 1.44 20.3 NS
Inﬂuence of Hispanic ethnicity on CL/F CL¼u1*u2
HSP 7.11 1.60 25.0 ,0.05
Inﬂuence of Hispanic ethnicity on V/F V¼u1*u2
HSP 118 0.81 22.0 NS
Inﬂuence of Hispanic ethnicity on ka ka¼u1*u2
HSP 2.81 4.42 24.3 ,0.05
Inﬂuence of weight on CL/F CL¼u1+u2*(WT276.2) 7.81 0.13 28.3 ,0.01
Inﬂuence of weight of V/F V¼u1+u2*(WT276.2) 105 1.26 25.8 ,0.05
CL/F, apparent oral clearance; V/F, apparent volume of distribution; ka, absorption rate constant; u1: typical value of the parameter; u2, estimate of the factor
associated with the covariate; DOFV, change in objective function value; RTV, ritonavir; AUC0–24, area under the concentration–time curve over 24 h;
SQV, saquinavir; TDF, tenofovir; AFR, Black-African ethnicity; HSP, Hispanic ethnicity; WT, weight.
Table 2. Atazanavir parameter estimates and relative standard errors obtained from the ﬁnal population pharmacokinetic model
Parameter
Basic model Final model
estimate RSE (%)
a estimate RSE (%)
a
CL/F (L/h) 7.6 8 7.7 5
V/F (L) 103 6 103 13
ka (h
21) 3.5 55 3.4 34
Lag-time (h) 0.96 3 0.96 1
IIV CL/F (%) 48 36 29 59
IIV V/F (%) 48 53 48 37
IIV ka (%) 154 103 154 51
Residual error
proportional (%) 23 18 23 27
additional (mg/L) 0.08 84 0.08 38
Factor associated with RTV AUC0–24on ATV CL/F
b —— 20.8 13
RSE (%), relative standard error; CL/F, apparent oral clearance; V/F, apparent volume of distribution; ka, absorption rate constant; IIV, inter-individual
variability; AUC0–24, area under the concentration–time curve.
aRSE deﬁned as: (SEestimate/estimate)*100.
bRTVAUC0–24as a covariate not included in the basic model.
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post-dose and following a combination of samples taken 4 and
8 h post-dose (Figure 3). The predictive performance was better
for atazanavir AUC0–24 compared with trough concentrations
with 11 of 15 chosen timepoint combinations, providing both
precise and unbiased predictions (Table 4). For atazanavir
trough concentrations, none of the chosen timepoints
provided precise predictions (%RMSE 21.4–48.1); however,
67% (10 of 15) were unbiased.
External model validation
A 95% prediction interval was generated from 1000 simulations
of the lower dose atazanavir/ritonavir regimens (200/100 and
150/100 mg once daily), one proﬁle per patient (n¼46 patients;
46000 proﬁles in total) with covariate values of those individ-
uals used in the model building process (Figure 2). Data from 18
HIV-infected patients (2 female) administered atazanavir/ritona-
vir/saquinavir 200/100/1600 and 150/100/1600 mg once daily as
part of another external study
20 were superimposed on the 95%
prediction intervals. Median (range) age, weight and BMI were
44 years (23–63), 75 kg (46–95) and 24 kg/m
2 (14–32). All
patients had an undetectable viral load (, 50 copies/mL) with
the exception of two individuals with viral loads of 74 and
84 copies/mL and CD4 cell count ranged between 123 and
837 cells/mm
3. Median (range) ritonavir AUC0–24 was
9.06 mg.h/L (3.84–15.29) and 8.86 mg.h/L (2.36–15.06) for
200/100/1600 and 150/100/1600 mg once daily, respectively. A
total of 198 concentrations were available for the two lower
dose regimens with 3% and 4% of concentrations lying outside
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Figure 1. Goodness-of-ﬁt plots for the ﬁnal pharmacokinetic model illustrating (a) population predictions of atazanavir versus observed concentrations,
(b) individual predictions of atazanavir versus observed concentrations and (c) weighted residuals versus time post-dose. The ﬁne line describes the line of
unity and the bold line describes the line of regression.
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and 150/100 mg once daily, respectively (Figure 2). The ﬁnal
model provided an adequate ﬁt to the data with between 96%
and 97% of concentration data falling within the prediction
intervals for the two evaluated regimens.
Predictions of atazanavir trough concentrations and AUC0–24
were made using single measured concentrations from each
HIV-infected individual included in the external atazanavir/rito-
navir dataset (in combination with saquinavir; n¼18)
20 and then
compared with measured trough concentrations and AUC0–24
by means of %RMSE and %MPE as for the internal validation.
A similar scenario was observed as for that of the internal
validation based on single timepoint predictions (2, 4, 6, 8, 10
and 12 h post-dose). Precise and unbiased predictions of ataza-
navir AUC0–24 were obtained using the model and concen-
trations at 4, 6, 8, 10 and 12 h post-dose for 200/100 mg once
daily and at 4, 6, 8 and 10 h post-dose for 150/100 mg once
daily. As with atazanavir/ritonavir 300/100 mg once daily,
none of the trough predictions were precise (%RMSE 27.4–45.4
and 21.3–49.3 for 200/100 and 150/100 mg once daily, respect-
ively) with the exception of the 12 h post-dose for the 150/
100 mg regimen, which estimated atazanavir trough with pre-
cision and accuracy (%RMSE: 14.7; %MPE, 95% CI: 21.3,
28.3 to 5.6).
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Figure 2. Ninety-ﬁve percent prediction intervals (P2.5–P97.5) determined from simulated data of atazanavir/ritonavir administered at (a) 300/100 mg once
daily, (b) 200/100 mg once daily and (c) 150/100 mg once daily. Observed data are superimposed for the three evaluated regimens.
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A model has been developed and validated to describe ritonavir-
boosted atazanavir pharmacokinetics in healthy individuals and
HIV-infected patients. Of the covariates available, only ritonavir
AUC0–24 was signiﬁcantly associated with atazanavir pharmaco-
kinetics, reducing the variability of atazanavir CL/F by 19%.
Furthermore, using the model, lower dose atazanavir/ritonavir
regimens (200/100 and 150/100 mg once daily) could be
simulated.
Atazanavir pharmacokinetics were best described by a
one-compartment model with ﬁrst-order absorption, which is
consistent with previous studies.
8,11,22 Population estimates for
CL/F were similar, and as with previous analyses, IIV of par-
ameters was wide, particularly ka (154% in this analysis versus
122%–156% in other studies).
11,22 This could be partially attrib-
uted to few samples being taken in the absorption phase;
however, characterization of the absorption phase was not the
main focus of this analysis. Atazanavir absorption can be
affected by food intake; however, all individuals included in the
model-building process were part of clinical studies where food
intake was standardized and carefully controlled for all partici-
pants. Furthermore, atazanavir absorption is highly dependent on
gut pH, which will be variable between subjects. The median
(range) individual estimate of half-life was 8.9 h (4.4–24.9) and
consistent with that reported in a population analysis by
Colombo et al. (8.8 h).
11
There are data suggesting that atazanavir concentrations are
lower in HIV patients compared with that in healthy individ-
uals.
1,2 Atazanavir minimum concentrations are more affected
( 50% lower) than peak concentrations ( 30%) and AUC0–24
( 20%), and the differences are more pronounced in the
absence of ritonavir boosting.
1 Atazanavir dissolution and
absorption relies heavily on an acidic environment and it has
been speculated that HIV patients produce less acid due to hypo-
chlorhydria,
23 therefore reducing atazanavir absorption. HIV
status was investigated as a covariate in this analysis, but
inclusion in the model did not signiﬁcantly improve the ﬁt when
assessed for CL/F, V/F or ka. Although it cannot be conﬁrmed, it
is plausible that HIV patients included in the analysis were not
suffering from signiﬁcant hypochlorhydria; therefore, no differ-
ences in pharmacokinetic parameters could be detected. Females
had  29% lower mean individual predicted CL/F compared
with males (6.40 versus 8.99 L/h), but this was not signiﬁcant,
which conﬁrm data by von Hentig et al.
24 No association was
observed between atazanavir pharmacokinetic parameters and
ethnicity; however, it is possible that the analysis is under-
powered to detect any disparities as the majority of the cohort
were Caucasian and only seven Black-Africans and six Hispanic
individuals were included. Moreover, no signiﬁcant differences
were observed following concomitant use of saquinavir
(1600 mg once daily), which is consistent with previous
studies,
15,16 or tenofovir (300 mg once daily). Tenofovir has
been shown to lower atazanavir concentrations
8,9; however, our
analysis is probably underpowered to evaluate this drug–drug
interaction as only 6 of the 46 individuals were receiving tenofo-
vir, although a study has shown that tenofovir does not affect
boosted atazanavir concentrations.
25 Not surprisingly, ritonavir
AUC0–24 described some of the variability in atazanavir
pharmacokinetics; however, other potentially important covari-
ates that were not measured may also contribute.
Atazanavir/ritonavir has the lowest pill burden of all protease
inhibitors, has a favourable lipid proﬁle and is suitable for once-
daily dosing. For some patients, toxicity due to hyperbilirubin-
aemia may be problematic and rather than switch therapies there
could be potential for dose reduction, as lower ritonavir-boosted
Table 4. Predictive performance of the ﬁnal model to predict atazanavir trough concentration (Ctrough) and area under the concentration–
time curve (AUC0–24) from a single sample or combination of two samples
Time (h)
Atazanavir Ctrough prediction Atazanavir AUC0–24 prediction
%RMSE %MPE (95% CI) %RMSE %MPE (95% CI)
2 21.4 0.1 (27.7 to 7.9) 11.8 23.1 (27.3 to 1.0)
4 27.9 23.2 (213.3 to 6.9) 8.3 2.1 (21.0 to 4.9)
6 48.1 27.1 (224.4 to 10.2) 6.8 21.1 (23.7 to 1.2)
8 42.1 27.8 (222.9 to 7.2) 6.4 22.3 (24.1 to 0.4)
10 31.4 26.5 (217.7 to 4.6) 8.5 22.0 (25.0 to 1.0)
12 27.3 210.2 (219.4 to 20.9) 8.6 24.1 (26.9 to 21.4)
2, 4 24.2 20.7 (29.5 to 8.2) 8.5 1.7 (21.4 to 4.7)
2, 6 22.9 0.2 (28.2 to 8.5) 7.8 22.2 (25.0 to 0.5)
2, 8 24.5 23.1 (211.9 to 3.4) 7.4 23.8 (26.1 to 21.5)
2, 10 26.8 26.1 (215.6 to 3.4) 8.3 24.5 (27.1 to 22.0)
2, 12 24.3 29.7 (217.8 to 21.6) 9.5 26.6 (29.1 to 24.1)
4, 6 42.5 211.3 (226.2 to 3.6) 6.4 0.1 (22.4 to 2.2)
4, 8 33.1 212.7 (223.8 to 21.6) 5.6 20.9 (22.9 to 1.1)
4, 10 28.8 212.2 (221.7 to 22.7) 6.4 20.7 (23.0 to 1.6)
4, 12 26.0 216.4 (223.7 to 29.1) 4.8 22.1 (23.7 to 20.6)
Values in bold type are precise (%RMSE,15%) and unbiased (%MPE not signiﬁcantly different from zero).
Ctrough, concentration at the end of the dosing interval, i.e. 24 h post-dose; AUC0–24, area under the concentration–time curve over 24 h; %RMSE, root mean
square relative prediction error (precision); %MPE, mean relative prediction error (bias); CI, conﬁdence interval.
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1240atazanavir doses have been associated with lesser increases in
total and indirect bilirubin.
20 Furthermore, a small pilot study in
HIV-infected Thai patients (n¼14) investigated the feasibility
of using lower dose atazanavir/ritonavir (200/100 mg once daily)
as an alternative to indinavir/ritonavir (400/100 mg twice daily),
reducing pill burden and costs and improving tolerability.
26
All patients studied obtained trough concentrations above the
recommended minimum effective concentration (MEC) for
atazanavir (0.15 mg/L) and viral loads ,50 copies/mL coupled
with signiﬁcant increases in CD4 cell count.
26 Here, the ﬁnal
model simulated atazanavir/ritonavir proﬁles dosed at 200/100
and 150/100 mg once daily; however, concern surrounds
whether at lower atazanavir/ritonavir doses trough concentrations
can remain above the MEC of 0.15 mg/L for viral suppression.
Of the 46000 simulated proﬁles for each of the three evaluated
regimens, 14%, 20% and 24% of trough concentrations
were ,0.15 mg/L for atazanavir/ritonavir 300/100, 200/100 and
150/100 mg once daily, respectively. Lower atazanavir/ritonavir
doses may be suitable for some patients; however, efﬁcacy data
are required.
As atazanavir is administered once daily and many patients
choose to take their medication in the evening, obtaining a
trough concentration in the clinic for TDM can be problematic.
It would therefore be advantageous to predict trough concen-
trations from a single sample or even estimate AUC0–24, which
would not only beneﬁt TDM interpretation but would be of par-
ticular use for clinical studies incorporating genomic analyses to
allow greater patient recruitment, or for studies in resource-
limited settings. Solas et al.
22 recently described a pharmaco-
kinetic model for atazanavir that allows Bayesian estimation of
atazanavir trough, although we await details of the precision and
accuracy of this approach. Taking into consideration that full
pharmacokinetic proﬁles can have an erratic appearance, model
capability to determine trough concentrations from single
samples should be evaluated. We therefore used our model and
single or a combination of two samples to predict trough con-
centrations and AUC0–24 of the HIV patients included in the
model for which these parameters were already known. Overall,
prediction of AUC0–24 was good for the majority of timepoints,
with 73% of predictions being both precise and unbiased;
however, predictions of trough concentrations tended to be
unbiased but not precise, based on %RMSE and %MPE criteria.
The same was true for predictions of trough and AUC0–24 for
200/100 and 150/100 mg, respectively. The model provides an
adequate ﬁt to the data, conﬁrmed by the validation process;
however, a number of concentration–time proﬁles were incon-
sistent, potentially making predictions of trough concentrations
more difﬁcult compared with prediction of exposure. Overall,
the analysis conﬁrms that predictions of atazanavir CL/F from
sparse samples were acceptable as CL/F is a function of the area
under the curve and dose of drug; however, estimation of trough
concentrations from sparse sampling was not consistent, with
predictions potentially being more sensitive to high variability in
atazanavir absorption.
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Figure 3. Individual predictions versus observed atazanavir trough (Ctrough) using samples taken at (a) 4 h post-dose and (b) 4 and 8 h post-dose, and
individual predicted versus observed atazanavir area under the curve (AUC0–24) using samples taken at (c) 4 h post-dose and (d) 4 and 8 h post-dose (n¼30).
The ﬁne line describes the line of unity and the bold line describes the line of regression.
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1241In conclusion, a population pharmacokinetic model to charac-
terize ritonavir-boosted atazanavir (300/100 mg once daily) in
HIV-infected patients and healthy volunteers has been developed
and validated. Ritonavir AUC0–24 described some of the varia-
bility in atazanavir concentrations; however, covariates not cap-
tured in this study should be investigated. The model can be
used to simulate lower dose atazanavir concentrations boosted
with ritonavir; however, prediction of trough concentrations
from sparse sampling may be limited. Successful prediction of
AUC0–24 from sparse sampling would be advantageous, particu-
larly when conducting pharmacokinetic studies in resource-
limited settings, and would also be useful to investigate optimal
sampling strategies for clinical studies where exposure is the
parameter of interest.
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